Humana (HUM) vs Labcorp (LH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Humana (HUM) has outperformed Labcorp (LH) over the past year, gaining 71.7% versus a gain of 38.2%. Over five years, LH leads with a +47.7% price change compared with -9.0% for HUM. Humana is the larger company by market cap ($46.84 billion vs $29.81 billion), about 1.6 times the size.
On valuation, Labcorp trades at a lower forward P/E (18.7x vs 21.1x for Humana). Humana offers the higher dividend yield (0.91% vs 0.78%). Labcorp converts more of its revenue into profit, with a net margin of 6.3% versus 0.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HUM | LH |
|---|---|---|
| Share price | $390.00 | $367.13 |
| Market cap | $46.84B | $29.81B |
| 1-day change | +2.63% | -0.47% |
| YTD return | +52.27% | +46.34% |
| 1-year return | +71.73% | +38.21% |
| 5-year return | -8.98% | +47.71% |
| P/E ratio (TTM) | 38.05 | 30.09 |
| Forward P/E | 21.06 | 18.73 |
| EPS (TTM) | $10.25 | $12.20 |
| Dividend yield | 0.91% | 0.78% |
| Annual dividend | $3.54 | $2.88 |
| Revenue (latest FY) | $129.66B | $13.95B |
| Revenue growth (YoY) | +10.11% | +7.25% |
| Net income (latest FY) | $1.19B | $876.50M |
| Gross margin | — | 28.76% |
| Operating margin | 2.09% | 9.92% |
| Net margin | 0.92% | 6.28% |
| 52-week high | $462.87 | $375.10 |
| 52-week low | $163.11 | $245.00 |
| Distance from 52-week high | -15.74% | -2.12% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +30.98% | +6.25% |
| Average volume | 1.46M | 744.44K |
| Shares outstanding | 120.10M | 81.20M |
| Employees | 67,060 | 71,000 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HUM has outperformed LH by 33.5 percentage points over the past year.
- Humana trades at a higher earnings multiple (38.0x vs 30.1x trailing P/E).
- Labcorp is more profitable, keeping 6.3 cents of every revenue dollar as net income versus 0.9 cents for Humana.
About Humana
HUM stock →Humana Inc. provides medical and specialty insurance products in the United States.
Health Care · Medical Specialities · 67,060 employees
About Labcorp
LH stock →Labcorp Holdings Inc. provides laboratory services.
Health Care · Medical Specialities · 71,000 employees
HUM vs LH FAQ
Which is bigger, Humana or Labcorp?
Humana (HUM) is larger, with a market capitalization of $46.84B compared with $29.81B for Labcorp (LH).
Which stock has performed better over the past year, HUM or LH?
HUM returned +71.73% over the past 12 months, compared with +38.21% for LH (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HUM or LH?
LH has the lower trailing P/E at 30.1, versus 38.0 for HUM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Humana or Labcorp?
Humana has the higher yield at 0.91%, compared with 0.78% for Labcorp.
Are Humana and Labcorp in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.